A total of 24 patients with metastatic renal cell carcinoma were treated by recombinant interferon-α2b (IFN-α2b) in combination with 5-fluorouracil (5-FU) and mitomycin C (MMC). Combined treatment included IFN-α2b at 6 x 106 units per body, per day, administered intramuscularly, 5-FU at 500 mg/m2 per day, administered intravenously (days 1 to 5) and MMC 2 mg/m2 per day, administered intravenously (days 1 and 2), repeated every 28 days. Of the 22 evaluable patients, one showed CR and two showed PR, with a response rate of 13.6%. The response durations were 6, 7, and 40+ months. The median survival duration of eligible patients was 14.5 months (range 2 to 41+ months). The most frequent adverse reactions were gastrointestinal symptoms (83.3%), fatigue (70.8%), flu-like symptoms (62.5%) and bone marrow suppression (83.3%).
|Number of pages||6|
|Journal||Nishinihon Journal of Urology|
|Publication status||Published - 1994|
- mitomycin C
- renal cell carcinoma
ASJC Scopus subject areas